洛铂介入栓塞化疗对肝癌患者免疫功能及P53、Bcl-2、Caspase-8表达的调节作用  

Analysis of lobaplatin interventional chemoembolization on immune function and expression of P53,Bcl-2 and Caspase-8 in patients with liver cancer

作　　者：王忠 李玉强 WANG Zhong;LI Yu-qiang(Department of Xianyang Hospital of Yan′an University,General Surgery,Shanxi Yan′an,712000,China)

机构地区：[1]延安大学咸阳医院普通外科,陕西延安712000

出　　处：《中西医结合肝病杂志》2023年第10期886-889,共4页Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases

基　　金：陕西省重点研发计划项目(No.2019SF-523)。

摘　　要：目的:探讨洛铂介入栓塞化疗对肝癌患者免疫功能及P53、Bcl-2、Caspase-8表达的调节作用。方法:选取2017年12月至2019年12月我院84例肝癌患者进行前瞻性研究,以简单随机化法分为观察组(n=42)、对照组(n=42)。对照组患者采取奥沙利铂介入栓塞化疗,观察组患者采取洛铂介入栓塞化疗。比较两组患者疗效、毒副反应、生存率及治疗前后血清肿瘤标志物甲胎蛋白(AFP)、糖类抗原19-9(CA19-9)、α-L-岩藻糖苷酶(AFU)表达水平,免疫功能指标细胞免疫(CD4^(+)、CD4^(+)/CD8^(+))、体液免疫(IgG、IgA、IgM)、血清P53、Bcl-2、Caspase-8表达水平。结果:两组患者疾病控制率比较,差异无统计学意义(P>0.05);观察组患者胃肠道反应、外周神经毒性发生率低于对照组(P<0.05);治疗后两组患者血清AFP、CA19-9、AFU水平均低于治疗前(P<0.05),但组间差异无统计学意义(P>0.05);治疗后观察组患者CD4^(+)、CD4^(+)/CD8^(+)、IgG、IgA、IgM水平高于对照组(P<0.05);治疗后两组患者血清Bcl-2表达均低于治疗前,血清P53、Caspase-8表达高于治疗前(P<0.05),但组间差异无统计学意义(P>0.05);随访12个月,两组患者生存率差异无统计学意义(P>0.05)。结论:洛铂、奥沙利铂介入栓塞化疗治疗肝癌患者均可有效调节血清P53、Bcl-2、Caspase-8表达,近远期疗效相当,但洛铂介入栓塞化疗所致毒副反应更少,免疫抑制更轻。Objective:To investigate the regulation of lobaplatin interventional chemoembolization on the immune function and the expression of P53,Bcl-2 and Caspase-8 in patients with liver cancer.Methods:A prospective study was conducted on 84 patients with liver cancer in our hospital from December 2017 to December 2019,and they were divided into observation group(n=42)and control group(n=42)by simple randomization.The control group received oxaliplatin interventional chemoembolization,and the observation group received lobaplatin interventional embolization chemotherapy.The efficacy,side effects,survival rate,serum tumor markers[alpha-fetoprotein(AFP),carbohydrate antigen 19-9(CA19-9),α-L-fucosidase(AFU)]level,immune function indicators[cellular immunity(CD4+,CD4+/CD8+),humoral immunity(IgG,IgA,IgM)]and serum P53,Bcl-2,Caspase-8 expression before and after treatment were compared between the two groups.Results:There were no statistically significant difference in disease control rate between the two groups(P>0.05).The incidence of gastrointestinal reactions and peripheral neurotoxicity in the observation group was lower than that in the control group(P<0.05).After treatment,the serum levels of AFP,CA19-9 and AFU in the two groups were lower than before treatment(P<0.05),but the differences between the groups were not statistically significant(P>0.05).After treatment,the levels of CD4+,CD4+/CD8+,IgG,IgA and IgM in the observation group were higher than those in the control group(P<0.05).After treatment,the expression of serum Bcl-2 in the two groups was lower than before treatment,and the expression of serum P53 and Caspase-8 were higher than before treatment(P<0.05),but the differences between the groups were not statistically significant(P>0.05).After 12 months of follow-up,there was no statistically significant difference in survival rates between the two groups(P>0.05).Conclusion:Lobaplatin and oxaliplatin can effectively regulate the expression of serum P53,Bcl-2 and Caspase-8 in the treatment of liver cancer patien

关 键 词：洛铂 奥沙利铂 介入栓塞 肝癌 免疫功能 

分 类 号：R575[医药卫生—消化系统]